Tuesday, April 19, 2016 3:15:32 PM
11:42 AM ET 4/19/16 | S&P Capital IQ
Dr. Stephen Huhn, CMO of StemCells Inc (NASDAQ: STEM) provided additional details regarding the ongoing Phase II Pathway Study in chronic cervical spinal cord injuries at the annual meeting of the American Spinal Injury Association on April 15. Maxim's Jason Kolbert maintained a Buy rating on the company, with a price target of $3. Cohort I Results Kolbert mentioned that the presentation by Dr. Huhn "included a top line update for the six patients enrolled in open label Cohort I from the Pathway Study." The analyst went on to say that the six-month results from the Cohort I trial revealed improvement in muscle strength in five of the six patients, with improved performance on functional tasks being demonstrated by four of these five patients. "In addition, four of the six patients had improvement in the level of cord injury," Kolbert stated. StemCells expects to announced details of the final 12 month results for Cohort I later during the quarter. The Positives If the company's HuCNS-SC cells work "even moderately," Kolbert believes that it could prove to be a "blockbuster", given that the market is large, with significant upside possible for StemCells. Acquire Media
Recent STEM News
- Stem Announces PowerTrack™ APM for Comprehensive Solar and Storage Energy Portfolio Management • Business Wire • 05/02/2024 08:10:00 PM
- Stem Announces First Quarter 2024 Results • Business Wire • 05/02/2024 08:05:00 PM
- Stem Announces Appointment of AI Industry Leader as New Independent Director • Business Wire • 04/19/2024 08:30:00 PM
- Stem Announces First Quarter 2024 Earnings Results Conference Call • Business Wire • 04/16/2024 12:30:00 PM
- Stem’s PowerBidder™ Pro Selected by Two CCAs in CAISO • Business Wire • 03/19/2024 12:30:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/11/2024 02:24:51 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:43:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:36:56 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:36:38 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:35:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:34:55 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:34:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/08/2024 09:33:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/07/2024 10:04:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:25:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:25:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:23:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:22:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:22:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:20:25 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 05:18:17 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:27:52 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/05/2024 01:26:31 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM